Heron Therapeutics receives Nasdaq minimum bid price deficiency notice
Heron Therapeutics received notice from Nasdaq on June 25, 2026, that the closing bid price of its common shares fell below the $1.00 per share minimum for continued listing on The Nasdaq Capital Market during the May 12 to June 24, 2026 period. The company has until December 22, 2026, to cure the deficiency by achieving a closing bid price of at least $1.00 per share for a minimum of ten consecutive trading days. Trading in the stock will continue on Nasdaq under the symbol HRTX during the compliance period.
Key facts
- Closing bid price fell below $1.00 per share for 30 consecutive trading days from May 12, 2026 to June 24, 2026
- 180 calendar day compliance period ending December 22, 2026
- Must achieve $1.00 or higher closing bid price for minimum of ten consecutive trading days to regain compliance
- Company may be eligible for an additional 180 calendar day compliance period if it meets other listing standards
- Company intends to monitor share price and explore available options to regain compliance
Why it matters
Heron Therapeutics has six months to restore its stock price above the $1.00 threshold or face delisting from Nasdaq; failure to cure during the initial period would require meeting all other listing standards and potentially executing a reverse stock split to qualify for a second compliance period.
Share
Derived from 8-K filed 2026-06-25. Not investment advice. View the source filing on SEC.gov →